Net turnover grew 7.5% to €602.75 million, driven by dermatology sales in Europe, with profit after tax up 37.9% to €60.9 million. Strong operating cash flow increased liquidity to €354.6 million, and R&D advanced with positive Phase 3 results for Ebglyss.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.